Kang N, Jeon K, Kim H, et al. - Given the challenges in treating mycobacterium abscessus-pulmonary disease (MABS-PD) due to its resistance to antibiotics, researchers here examine the outcomes of treatment-naïve MABS-PD patients treated with inhaled amikacin-containing multidrug regimens. This prospective observational cohort study was performed including 82 treatment-naïve MABS-PD patients who were treated with regimens containing inhaled amikacin with or without clofazimine. During the initial phase, intravenous amikacin, imipenem (or cefoxitin) and oral azithromycin were provided to all patients. Cases of (i) M. abscessus subspecies abscessus (here M. abscessus) or (ii) M. abscessus subspecies massiliense (here M. massiliense) with cavitary lesions, additionally received oral clofazimine. During the continuation phase, change in amikacin was done from injection to inhalation form. Outcomes suggest that favorable treatment outcomes are achieved in M. massiliense-PD in correlation with providing inhaled amikacin with or without clofazimine in the regimen. However, there is a necessity for more effective treatments for M. abscessus-PD.